Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?
10:53am, Friday, 29'th Jul 2022
Here is how Corcept Therapeutics (CORT) and Alkermes (ALKS) have performed compared to their sector so far this year.
3 Biotech Stocks Outperforming a Bear Market
07:50am, Friday, 15'th Jul 2022
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. The post 3 Biotech Stocks Outperformin
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
01:13pm, Tuesday, 05'th Jul 2022
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well.
Corcept Therapeutics (CORT) Q1 2022 Earnings Call Transcript
02:30am, Saturday, 07'th May 2022 The Motley Fool
CORT earnings call for the period ending March 31, 2022.
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
03:11pm, Friday, 06'th May 2022 Zacks Investment Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
12:48pm, Friday, 06'th May 2022
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2022 Results - Earnings Call Transcript
10:48pm, Thursday, 05'th May 2022
Corcept Therapeutics Incorporated. (NASDAQ:CORT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Off
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
10:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
09:45pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 28'th Apr 2022
MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on
3 Small-Cap Medical Stocks With Big Momentum
03:15pm, Wednesday, 27'th Apr 2022 The Motley Fool
Now is a good time to take a closer look at these stocks.
Corcept Therapeutics Announces Appointment of Three Senior Leaders
08:05pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
Key Hires Bring Diverse Expertise to Commercial and Development Initiatives Key Hires Bring Diverse Expertise to Commercial and Development Initiatives
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
04:54pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
02:18pm, Tuesday, 05'th Apr 2022
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
